Cortical Organoid Model of PPP2R5D Genetic Intellectual Disability Models Disease Severity Phenotype
Yuxin DuiD, Mandeep Singh, Mandar M. Patil, Isaac J. VillegasiD, Adriana Portillo, Kyle Shang, Roy Ben‐ShalomiD, Julian A. N. M. HalmaiiD, Kyle D. FinkiD
Abstract
Jordans Syndrome (JS) is a rare, neurodevelopmental disorder caused by de novo missense mutations in protein phosphatase 2 regulatory subunit Bdelta (PPP2R5D). JS is characterized by severe neurological impairments starting in early life. PPP2R5D encodes for B56{delta}, one of the regulatory subunits of protein phosphatase 2A (PP2A). PP2A is a heterotrimeric protein serine/threonine phosphatase that is highly expressed in the brain and the liver. Past studies have focused on PP2As role in liver and little is known about the holoenzymes behavior in neuronal cells. Although B56{delta} is known to play an important role in the substrate specificity of PP2A, the identification of validated downstream substrates in JS remains unclear. To better understand how the mutations affect neuronal cells, we developed cerebral cortical-like organoids from an engineered allele series of the most common JS mutations to characterize the physiological changes throughout different stages of neurodevelopment. Organoids were assessed for transcriptomic, protein, and electrophysiological changes utilizing bulk RNA sequencing, immunocytochemistry, Western Blot, and high-density MicroElectrode Array. The results identify differentially expressed genes and translated proteins, potential neuronal substrates, and significant electrophysiological signatures that suggest mutations in B56{delta} lead to variant-specific dysfunction of PP2A. Overexpression of PPP2R5D through AAV transduction of organoids rescued several phenotypes in the variants, suggesting different pathogenetic etiology underneath. Our findings successfully characterized cerebral cortical-like organoids in JS cell lines and demonstrated its potential as a model for studying neurodevelopmental disorder and for screening therapeutic approaches.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quantitative proteomics and phosphoproteomics of PPP2R5D variants reveal deregulation of RPS6 phosphorylation through converging signaling cascades
K. A. Smolen, C. M. Papke, … A. N. Kettenbach·bioRxiv·Mar 27, 2023
- Proteomics and phosphoproteomics profiling in glutamatergic neurons and microglia in an iPSC model of Jansen de Vries Syndrome
Jennifer T. Aguilan, Erika Pedrosa, … Herbert M. Lachman·bioRxiv·Jul 8, 2023
- Extended regulation interface coupled to the allosteric network and disease mutations in the PP2A-B56δ holoenzyme
C.-G. Wu, V. K. Balakrishnan, … Y. Xing·bioRxiv·Mar 9, 2023
- Human organoid model of PCH2a recapitulates brain region-specific pathology
Theresa Kagermeier, Stefan Hauser, … Simone Mayer·Disease Models & MechanismsPeer-reviewed·Jul 1, 2024
- Functional analysis of a novel de novo variant in PPP5C associated with microcephaly, seizures, and developmental delay
Sara M. Fielder, Jill Anne Rosenfeld, … Stephen C. Pak·Molecular Genetics and MetabolismPeer-reviewed·Mar 21, 2022
- Parkinson’s disease phenotypes in patient specific brain organoids are improved by HP-β-CD treatment
Javier Jarazo, Kyriaki Barmpa, … Jens Christian Schwamborn·bioRxiv·Oct 22, 2019